Select EZH2 inhibitors enhance viral mimicry effects of DNMT inhibition through a mechanism involving NFAT:AP-1 signaling.

Autor: Chomiak AA; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI 49503, USA., Tiedemann RL; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI 49503, USA., Liu Y; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI 49503, USA., Kong X; Department of Oncology, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA., Cui Y; Department of Oncology, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA., Wiseman AK; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI 49503, USA., Thurlow KE; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI 49503, USA., Cornett EM; Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indiana University, Indianapolis, IN 46202, USA., Topper MJ; Department of Oncology, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA., Baylin SB; Department of Oncology, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA., Rothbart SB; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI 49503, USA.

Publikováno v: Science advances [Sci Adv] 2024 Mar 29; Vol. 10 (13), pp. eadk4423. Date of Electronic Publication: 2024 Mar 27.

DNA methylation dynamics and dysregulation delineated by high-throughput profiling in the mouse.

Autor: Zhou W; Center for Computational and Genomic Medicine, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Hinoue T; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI 49503, USA., Barnes B; Illumina, Inc., Bioinformatics and Instrument Software Department, San Diego, CA 92122, USA., Mitchell O; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI 49503, USA., Iqbal W; Center for Computational and Genomic Medicine, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA., Lee SM; Center for Computational and Genomic Medicine, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA., Foy KK; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI 49503, USA., Lee KH; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI 49503, USA., Moyer EJ; Center for Computational and Genomic Medicine, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA., VanderArk A; Department of Metabolism and Nutritional Programming, Van Andel Institute, Grand Rapids, MI 49503, USA., Koeman JM; Genomics Core, Van Andel Institute, Grand Rapids, MI 49503, USA., Ding W; Center for Computational and Genomic Medicine, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA., Kalkat M; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI 49503, USA., Spix NJ; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI 49503, USA., Eagleson B; Vivarium and Transgenics Core, Van Andel Institute, Grand Rapids, MI 49503, USA., Pospisilik JA; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI 49503, USA., Szabó PE; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI 49503, USA., Bartolomei MS; Department of Cell and Developmental Biology, Epigenetics Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA., Vander Schaaf NA; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI 49503, USA.; Present address: Department of Biological Sciences, Olivet Nazarene University, Bourbonnais, IL 60914, USA., Kang L; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI 49503, USA., Wiseman AK; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI 49503, USA., Jones PA; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI 49503, USA., Krawczyk CM; Department of Metabolism and Nutritional Programming, Van Andel Institute, Grand Rapids, MI 49503, USA., Adams M; Genomics Core, Van Andel Institute, Grand Rapids, MI 49503, USA., Porecha R; Illumina, Inc., Bioinformatics and Instrument Software Department, San Diego, CA 92122, USA., Chen BH; FOXO Technologies Inc., Minneapolis, MN 55402, USA., Shen H; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI 49503, USA., Laird PW; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI 49503, USA.; Lead contact.

Publikováno v: Cell genomics [Cell Genom] 2022 Jul 13; Vol. 2 (7).

Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia.

Autor: Pappalardi MB; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Keenan K; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Cockerill M; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK.; These authors contributed equally: Mark Cockerill, Wendy A. Kellner., Kellner WA; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA.; These authors contributed equally: Mark Cockerill, Wendy A. Kellner., Stowell A; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK., Sherk C; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Wong K; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Pathuri S; Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Briand J; Medicinal Science & Technology, GlaxoSmithKline, Collegeville, PA, USA., Steidel M; Cellzome GmbH, Functional Genomics, GlaxoSmithKline, Heidelberg, Germany., Chapman P; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK., Groy A; Future Pipeline Discovery, GlaxoSmithKline, Collegeville, PA, USA., Wiseman AK; Center for Epigenetics, Van Andel Research Institute, Grand Rapids, MI, USA., McHugh CF; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Campobasso N; Medicinal Science & Technology, GlaxoSmithKline, Collegeville, PA, USA., Graves AP; Medicinal Science & Technology, GlaxoSmithKline, Collegeville, PA, USA., Fairweather E; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK., Werner T; Cellzome GmbH, Functional Genomics, GlaxoSmithKline, Heidelberg, Germany., Raoof A; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK., Butlin RJ; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK., Rueda L; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Horton JR; Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fosbenner DT; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Zhang C; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Handler JL; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Muliaditan M; Drug Metabolism and Pharmacokinetics Modelling, GlaxoSmithKline, Stevenage, UK., Mebrahtu M; Medicinal Science & Technology, GlaxoSmithKline, Collegeville, PA, USA., Jaworski JP; Medicinal Science & Technology, GlaxoSmithKline, Collegeville, PA, USA., McNulty DE; Medicinal Science & Technology, GlaxoSmithKline, Collegeville, PA, USA., Burt C; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK., Eberl HC; Cellzome GmbH, Functional Genomics, GlaxoSmithKline, Heidelberg, Germany., Taylor AN; Medicinal Science & Technology, GlaxoSmithKline, Collegeville, PA, USA., Ho T; Medicinal Science & Technology, GlaxoSmithKline, Collegeville, PA, USA., Merrihew S; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Foley SW; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Rutkowska A; Cellzome GmbH, Functional Genomics, GlaxoSmithKline, Heidelberg, Germany., Li M; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Romeril SP; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Goldberg K; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK., Zhang X; Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kershaw CS; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK., Bantscheff M; Cellzome GmbH, Functional Genomics, GlaxoSmithKline, Heidelberg, Germany., Jurewicz AJ; Medicinal Science & Technology, GlaxoSmithKline, Collegeville, PA, USA., Minthorn E; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Grandi P; Cellzome GmbH, Functional Genomics, GlaxoSmithKline, Heidelberg, Germany., Patel M; Medicinal Science & Technology, GlaxoSmithKline, Collegeville, PA, USA., Benowitz AB; Future Pipeline Discovery, GlaxoSmithKline, Collegeville, PA, USA., Mohammad HP; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Gilmartin AG; Future Pipeline Discovery, GlaxoSmithKline, Collegeville, PA, USA., Prinjha RK; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Ogilvie D; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK., Carpenter C; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Heerding D; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Baylin SB; Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA., Jones PA; Center for Epigenetics, Van Andel Research Institute, Grand Rapids, MI, USA., Cheng X; Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX, USA., King BW; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Luengo JI; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Jordan AM; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK., Waddell I; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK., Kruger RG; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., McCabe MT; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA.

Publikováno v: Nature cancer [Nat Cancer] 2021 Oct; Vol. 2 (10), pp. 1002-1017. Date of Electronic Publication: 2021 Sep 27.